RG3 Snake Venom
/ Synthetic snake-venom mimetic peptide; topical cosmeticALIAS · RG3 Snake Venom Analog · Venombotox alternative
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Vendor-marketed synthetic snake-venom mimetic peptide promoted as a topical 'Botox alternative.' No identifiable PubMed-indexed primary literature characterising the specific RG3 vendor compound, its sequence, mechanism in independent assays, or topical efficacy versus placebo. Mechanistic claims are inherited by analogy from the broader waglerin / Syn-Ake nAChR-antagonist class.
Vendor literature positions RG3 within the same broad class as Syn-Ake-style waglerin mimetics — competitive antagonism at the muscle-type nicotinic acetylcholine receptor, with the implied topical claim of attenuated facial mimetic-muscle contraction. The specific vendor compound's sequence, receptor-binding characterisation, and topical penetration have not been described in independent primary literature.
None substantive. RG3 is a vendor-marketed compound with effectively no published characterisation in the indexed primary literature. Buyers cannot verify identity, purity, or pharmacology against a published reference standard.
No formal safety database. Systemic-exposure concerns from topical application are presumed low by analogy to other snake-venom mimetic peptide cosmetics, but no independent data exist for this specific compound.
Regulatory status
- FDA status:
- Not FDA-approved
The compound is sold on the strength of class-level claims (waglerin / nAChR-antagonist mimetics) rather than direct evidence for the specific RG3 vendor material. Identity testing against any published reference standard is not possible because no such standard appears in the indexed literature.